BPH is a relatively frequent disease and the costs associated with its treatment contribute in a major way to the costs of treatment of urological patients. Alternative medicamentous and less invasive therapeutic methods led to a decline in the rising number of prostatectomies but did not lead to the assumed decline of costs, on the contrary. The question remains how to rationalise to a maximum extent these costs which should be met from public resources, in particular in this disease which usually does not threaten the patient's health nor life. Allocation of constant resources from the gross national product to health services is an important problem also in conjunction with the diagnosis and treatment of BPH.
|Number of pages||4|
|Publication status||Published - 1999|
- Benign hyperplasia of the prostate
- Economic aspects
ASJC Scopus subject areas